What question did this study set out to answer?

This research focuses on evaluating the effectiveness of PD-1 and CTLA-4 inhibitors in varying colorectal cancer types.

April 4, 2026

Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling

Puntos clave

This research focuses on evaluating the effectiveness of PD-1 and CTLA-4 inhibitors in varying colorectal cancer types.
Analyzed the effects of PD-1 and CTLA-4 inhibitors in MSI-H/dMMR and MSS colorectal cancer.
Compared survival benefits in patients with different genetic backgrounds.
Explored innovative combination therapies to overcome resistance.
Demonstrated long-term clinical efficacy and survival benefits in MSI-H/dMMR colorectal cancer.
Limited response observed in MSS metastatic colorectal cancer.
Highlight the need for new combination therapies to treat resistance.

Resumen

The combination of PD-1 and CTLA-4 inhibitors in MSI-H/dMMR metastatic colorectal cancer has demonstrated long-term clinical efficacy and a genuine survival benefit. However, in MSS metastatic colorectal cancer, there has been limited response, emphasizing the importance of innovative combination therapies to address both primary and secondary resistance.

Me gusta

Guardar

Me gusta

Guardar

Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling

Puntos clave

Resumen

Cite This Study